Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

[Synergistic effect and mechanism of baicalein in combination with lenalidomide-induced apoptosis of myeloma cells].

Zhang RB, He L, Huang Z, Ma Z, Liu SQ.

Zhonghua Xue Ye Xue Za Zhi. 2013 Jun;34(6):546-7. doi: 10.3760/cma.j.issn.0253-2727.2013.06.021. Chinese. No abstract available.

PMID:
23827119
2.

Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma.

van der Spek E, Bloem AC, Lokhorst HM, van Kessel B, Bogers-Boer L, van de Donk NW.

Leuk Res. 2009 Jan;33(1):100-8. doi: 10.1016/j.leukres.2008.06.001. Epub 2008 Jul 14.

PMID:
18621417
3.

Lenalidomide mode of action: linking bench and clinical findings.

Davies F, Baz R.

Blood Rev. 2010 Nov;24 Suppl 1:S13-9. doi: 10.1016/S0268-960X(10)70004-7. Review.

PMID:
21126632
4.

Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function.

Gandhi AK, Kang J, Capone L, Parton A, Wu L, Zhang LH, Mendy D, Lopez-Girona A, Tran T, Sapinoso L, Fang W, Xu S, Hampton G, Bartlett JB, Schafer P.

Curr Cancer Drug Targets. 2010 Mar;10(2):155-67.

PMID:
20088798
5.

Role of Baicalein in the regulation of proliferation and apoptosis in human myeloma RPMI8226 cells.

Li QB, You Y, Chen ZC, Lü J, Shao J, Zou P.

Chin Med J (Engl). 2006 Jun 5;119(11):948-52. No abstract available.

PMID:
16780776
6.

Lovastatin and thalidomide have a combined effect on the rate of multiple myeloma cell apoptosis in short term cell cultures.

Dmoszynska A, Podhorecka M, Klimek P, Grzasko N.

Eur J Clin Pharmacol. 2006 Apr;62(4):325-9. Epub 2006 Mar 8.

PMID:
16523333
7.

PPARbeta-mediated growth suppression of baicalein and dexamethasone in human myeloma cells.

Otsuyama KI, Ma Z, Abroun S, Amin J, Shamsasenjan K, Asaoku H, Kawano MM.

Leukemia. 2007 Jan;21(1):187-90. Epub 2006 Nov 2. No abstract available.

PMID:
17082776
8.

In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines.

Schmidt-Hieber M, Dabrowski R, Weimann A, Aicher B, Lohneis P, Busse A, Thiel E, Blau IW.

Invest New Drugs. 2012 Apr;30(2):480-9. doi: 10.1007/s10637-010-9576-2. Epub 2010 Nov 16.

PMID:
21080211
9.

Lenalidomide affect expression level of cereblon protein in multiple myeloma cell line RPMI8226.

Yang DY, Ren JH, Guo XN, Guo XL, Cai XY, Guo XF, Zhang JN.

Genet Mol Res. 2015 Oct 29;14(4):13588-94. doi: 10.4238/2015.October.28.19.

10.

Thalidomide and lenalidomide: Mechanism-based potential drug combinations.

Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC.

Leuk Lymphoma. 2008 Jul;49(7):1238-45. doi: 10.1080/10428190802005191. Review.

PMID:
18452080
11.

Novel tubulin-polymerization inhibitor derived from thalidomide directly induces apoptosis in human multiple myeloma cells: possible anti-myeloma mechanism of thalidomide.

Iguchi T, Yachide-Noguchi T, Hashimoto Y, Nakazato S, Sagawa M, Ikeda Y, Kizaki M.

Int J Mol Med. 2008 Feb;21(2):163-8.

PMID:
18204782
12.

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.

Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP, Anderson KC.

Blood. 2002 Jun 15;99(12):4525-30.

13.

Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.

Munemasa S, Sakai A, Kuroda Y, Okikawa Y, Katayama Y, Asaoku H, Kubo T, Shimose S, Kimura A.

Int J Oncol. 2008 Jul;33(1):129-36. Erratum in: Int J Oncol. 2008 Dec;33(6):1315.

PMID:
18575758
14.

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.

Raje N, Kumar S, Hideshima T, Ishitsuka K, Chauhan D, Mitsiades C, Podar K, Le Gouill S, Richardson P, Munshi NC, Stirling DI, Antin JH, Anderson KC.

Blood. 2004 Dec 15;104(13):4188-93. Epub 2004 Aug 19.

15.

Lenalidomide in the treatment of multiple myeloma: a review.

Armoiry X, Aulagner G, Facon T.

J Clin Pharm Ther. 2008 Jun;33(3):219-26. doi: 10.1111/j.1365-2710.2008.00920.x. Review.

PMID:
18452408
16.

In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.

Ocio EM, Vilanova D, Atadja P, Maiso P, Crusoe E, Fernández-Lázaro D, Garayoa M, San-Segundo L, Hernández-Iglesias T, de Alava E, Shao W, Yao YM, Pandiella A, San-Miguel JF.

Haematologica. 2010 May;95(5):794-803. doi: 10.3324/haematol.2009.015495. Epub 2009 Nov 30.

17.

[The use of lenalidomide in the treatment of multiple myeloma].

Holánek M, Hájek R.

Klin Onkol. 2010;23(2):67-72. Review. Czech.

PMID:
20465083
18.

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.

Tai YT, Li XF, Catley L, Coffey R, Breitkreutz I, Bae J, Song W, Podar K, Hideshima T, Chauhan D, Schlossman R, Richardson P, Treon SP, Grewal IS, Munshi NC, Anderson KC.

Cancer Res. 2005 Dec 15;65(24):11712-20.

19.

Induction of apoptosis in multiple myeloma cells by a statin-thalidomide combination can be enhanced by p38 MAPK inhibition.

Slawinska-Brych A, Zdzisinska B, Mizerska-Dudka M, Kandefer-Szerszen M.

Leuk Res. 2013 May;37(5):586-94. doi: 10.1016/j.leukres.2013.01.022. Epub 2013 Feb 20.

PMID:
23434428
20.

Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo.

Zhang L, Qian Z, Cai Z, Sun L, Wang H, Bartlett JB, Yi Q, Wang M.

Am J Hematol. 2009 Sep;84(9):553-9. doi: 10.1002/ajh.21468.

Supplemental Content

Support Center